Fundz

METiS Technologies secures RMB 400 million in Series D financing, co-led by Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund, to enhance its biopharmaceutical innovations.

PRIVATEAug 05, 2025

Amount Raised

¥400 Million

Round Type

Series D

BiotechnologyArtificial IntelligenceTherapeutics

Investors

Beijing Medical And Health Industry Investment FundDaxing Industrial Investment Fund

Description

METiS Technologies has successfully completed its RMB 400 million Series D financing round. This funding will accelerate its core strategic initiatives, including automation upgrades, pipeline development, and global partnerships. The round was co-led by the Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund. The new capital aims to advance METiS' position in the biopharmaceutical sector.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as METiS Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • Tahoe Therapeutics raised $30M (Funding Round) on August 11, 2025.
  • Revive Therapeutics raised $91K (Post-IPO Equity) on September 19, 2025.
  • Immuto Scientific raised $8M (Seed) on September 18, 2025.
  • ARTHEx Biotech raised $87M (Series B) on September 17, 2025.
  • Trially raised $4.7M (Seed) on September 16, 2025.
  • Lila Sciences raised $235M (Funding Round) on September 13, 2025.

Who to call at METiS Pharmaceuticals, and when

A new round usually means METiS Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day METiS Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at METiS Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at METiS Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

METiS Pharmaceuticals

About

METiS Technologies is a pioneering TechBio company unlocking a healthier world through AI-driven nanotechnology. At the intersection of artificial intelligence and nanomaterial science, METiS transforms the delivery and application of active agents across life forms. Founded by MIT-trained scientists, the company has developed three proprietary platforms—AiLNP for nucleic acid delivery system design, AiRNA for mRNA sequence optimization, and AiTEM for small molecule formulation. These platforms simulate and predict nanoscale interactions to enable the rational design of next-generation nanomaterials and therapeutics. METiS is advancing new possibilities in treating cancer, metabolic and autoimmune disorders, neurodegenerative conditions, and more.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment METiS Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for METiS Pharmaceuticals's next move

See what Strategic adds

METiS Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.